Speak With Admissions
Teen marijuana treatment may help when cannabis use is difficult to control, affects school or family life, or occurs alongside mental health concerns. You can request an assessment without first deciding whether your teen has an addiction or needs residential care.
At Rise Adolescent Treatment Center in Las Vegas, we provide specialized treatment for adolescents ages 12–17 with substance use, mental health, or co-occurring concerns. Our admissions team can discuss whether our services may fit your teen’s needs.
Cannabis use disorder involves problems related to cannabis use, including difficulty stopping despite consequences. Unsuccessful attempts to cut back or giving up valued activities can be reasons to seek assessment. Starting during adolescence and using more frequently are associated with greater risk (Centers for Disease Control and Prevention [CDC], 2024b).
A U.S. survey analysis found cannabis use disorder in an estimated 10.7% of adolescents ages 12–17 within their first year after starting use, compared with 6.4% of young adults. Those figures describe a specific time period after initiation, not the lifetime risk for every person who uses cannabis (Volkow et al., 2021).
Falling grades, irritability, or a changed friend group can have more than one explanation. Share specific observations and your teen’s account with the clinician so the assessment considers substance use and mental health together.
Cannabis can affect attention, memory, and learning while the brain is still developing (CDC, 2024b). A study following 799 initially cannabis-naive adolescents found an association between later cannabis use and greater thinning in parts of the brain’s outer layer, particularly prefrontal regions. The finding concerns a group-level pattern of brain development; it cannot determine an individual teen’s prognosis (Albaugh et al., 2021).
Tell the clinician which products were used, how often use occurs, and any noticeable reactions. If details are uncertain, let your teen describe them where possible.

Some teens say they use marijuana to sleep, manage stress, fit in, or stop thinking about difficult experiences. Ask what your teen hopes it will do and what they have noticed afterward.
You might say, “You have told me it helps you relax. I also notice mornings have become harder. I want us to understand both.” This acknowledges their experience and opens a discussion about effects on daily life.
Keep the first conversation focused on your teen’s experience. Ask which changes concern them and what would make speaking with a professional easier.
Ask the prescriber what each proposed medication is intended to treat.
Cannabis use has been linked with depression, social anxiety, and psychosis, although the relationships are not fully understood (CDC, 2024a). In a national adolescent survey, lifetime cannabis use was associated with about 3.3 times higher odds of severe major depressive disorder. Because this was a survey of co-occurring experiences, it does not show that cannabis caused later depression (Hinckley et al., 2023).
Potency and frequency also matter. A 2019 case-control study of adults found nearly five times higher odds of psychotic disorder among daily users of high-potency cannabis compared with never-users. This adult finding supports attention to product strength and use patterns, but is not a teen-specific risk estimate (King’s College London, 2019).
An assessment should consider the timing of symptoms, cannabis use, other substances, medical history, and prescribed medicines. Ask how the team will address concerns such as anxiety, depression, trauma, or ADHD alongside substance use.
New hallucinations, severe confusion, or other marked changes require prompt medical assessment.
Call 911 for immediate danger, trouble breathing, unresponsiveness, or another medical emergency. Do not assume a severe reaction will pass because the substance was described as marijuana.
For suicidal thoughts or emotional crisis in the United States, call or text 988.
Withdrawal after stopping or reducing cannabis can include irritability, sleep problems, anxiety, lower appetite, and cravings (National Library of Medicine, n.d.). Tell the clinician about these symptoms and any other substance use. Rise does not provide detox; any needed medical stabilization should be arranged with an appropriate provider before admission.
The assessment should guide the plan. Ask the provider how the treatment process will address substance use disorder, co occurring conditions, family communication, and the situations that make change difficult.
Useful questions include:
How will the team assess both substance abuse concerns and mental health issues?
How will our teen take part in setting goals and personalized treatment plans?
What evidence based practices and other therapeutic interventions are used, and why do they fit this situation?
What role will parents or guardians have in the recovery process and personal growth?
How will you review progress and respond to a return to use?
What role will group therapy or peer support have?
Who will provide follow-up after this program?
Ask the provider to explain the actual treatment methods. Research has studied motivational enhancement therapy combined with CBT, which helps adolescents explore reasons for change and practice coping skills (Dennis et al., 2004). Contingency management uses agreed rewards to reinforce treatment goals and has been included in cannabis treatment trials (Gray et al., 2025).
Family-based approaches also have evidence. In a European trial of ages 13–18, multidimensional family therapy reduced cannabis dependence more than individual psychotherapy. Among participants with more frequent use, it also produced a greater reduction in days of use (Rigter et al., 2013). Ask which approaches a program provides and how they fit your teen.
Cannabis concerns do not automatically require residential treatment. Some adolescents receive help through outpatient treatment. Others need more intensive support because of the combined picture of functioning, safety, substance use, and mental health.
Our treatment options at Rise include residential care, a partial hospitalization program (PHP), an intensive outpatient program (IOP), and standard outpatient care. We work with adolescents ages 12–17 using CBT, DBT skills, trauma-focused work, experiential therapy, and family therapy. We assess clinical fit and coordinate care for substance use and co-occurring mental health concerns.
We do not provide acute psychiatric hospitalization. Ask our admissions team what information is needed to evaluate fit and whether an outside medical assessment is necessary first.
At Rise, our board-certified adolescent psychiatry physician provides psychiatric support and medication management. When cannabis use occurs alongside another mental health concern, we can discuss treatment for both and how medication fits the plan.
There is no FDA-approved medication specifically for cannabis use disorder. N-acetylcysteine (NAC) has been studied, with mixed findings. A 2025 trial of 192 participants ages 14–21 found no advantage over placebo when NAC was paired with brief counseling and medical management, without contingency management. Earlier positive findings came from a different behavioral treatment setup (Gray et al., 2025). Ask the prescriber what each medication recommendation is intended to treat and how it will be monitored.
Ask how family therapy will support communication, what skills to practice outside sessions, and who will provide follow-up. The plan should connect treatment goals with school, relationships, and daily routines.
Ask the treating professional how to set clear expectations at home and respond to setbacks. Discuss boundaries and communication together so your teen understands both the expectations and the support available.
Ask what your teen wants to get back to, what feels difficult, and which supports they find useful. These questions can help the family move beyond arguments about cannabis and toward meaningful goals.
For the broader approach to alcohol and drug concerns, see teen substance use treatment at Rise.
An assessment can help your family understand the concern and compare appropriate treatment options. Call our admissions team confidentially to discuss whether Rise may be a suitable next step.
No. Frequency is relevant, but care decisions require a broader assessment. Ask the clinician to explain the recommended setting and alternatives.
Share that account with a qualified clinician and ask for an assessment of both concerns. Feeling short-term relief does not establish that cannabis is an appropriate anxiety treatment.
No. A medical professional should evaluate any need for withdrawal support or stabilization before admission to Rise.
Albaugh, M. D., Ottino-Gonzalez, J., Sidwell, A., Lepage, C., Juliano, A., Owens, M. M., Chaarani, B., Spechler, P., Fontaine, N., Rioux, P., Lewis, L., Jeon, S., Evans, A., D’Souza, D., Radhakrishnan, R., Banaschewski, T., Bokde, A. L. W., Quinlan, E. B., Conrod, P., . . . Garavan, H. (2021). Association of cannabis use during adolescence with neurodevelopment. JAMA Psychiatry, 78(9), 1031–1040. https://doi.org/10.1001/jamapsychiatry.2021.1258
Centers for Disease Control and Prevention. (2024a). Cannabis and mental health. https://www.cdc.gov/cannabis/health-effects/mental-health.html
Centers for Disease Control and Prevention. (2024b). Cannabis and teens. https://www.cdc.gov/cannabis/health-effects/cannabis-and-teens.html
Dennis, M., Godley, S. H., Diamond, G., Tims, F. M., Babor, T., Donaldson, J., Liddle, H., Titus, J. C., Kaminer, Y., Webb, C., Hamilton, N., & Funk, R. (2004). The Cannabis Youth Treatment (CYT) Study: Main findings from two randomized trials. Journal of Substance Abuse Treatment, 27(3), 197–213. https://doi.org/10.1016/j.jsat.2003.09.005
Gray, K. M., Tomko, R. L., Baker, N. L., McClure, E. A., McRae-Clark, A. L., & Squeglia, L. M. (2025). N-acetylcysteine for youth cannabis use disorder: Randomized controlled trial main findings. Neuropsychopharmacology, 50, 731–738. https://doi.org/10.1038/s41386-025-02061-y
Hinckley, J. D., Mikulich-Gilbertson, S. K., He, J.-P., Bhatia, D., Ellingson, J. M., Vu, B. N., Merikangas, K. R., & Sakai, J. T. (2023). Cannabis use is associated with depression severity and suicidality in the National Comorbidity Survey–Adolescent Supplement. JAACAP Open, 1(1), 24–35. https://doi.org/10.1016/j.jaacop.2023.02.002
King’s College London. (2019). High potency cannabis linked to higher rates of psychosis. https://www.kcl.ac.uk/news/high-potency-cannabis-linked-to-higher-rates-of-psychosis
National Library of Medicine. (n.d.). Cannabis. MedlinePlus. https://medlineplus.gov/cannabis.html
Rigter, H., Henderson, C. E., Pelc, I., Tossmann, P., Phan, O., Hendriks, V., Schaub, M., & Rowe, C. L. (2013). Multidimensional family therapy lowers the rate of cannabis dependence in adolescents: A randomised controlled trial in Western European outpatient settings. Drug and Alcohol Dependence, 130(1–3), 85–93. https://doi.org/10.1016/j.drugalcdep.2012.10.013
Volkow, N. D., Han, B., Einstein, E. B., & Compton, W. M. (2021). Prevalence of substance use disorders by time since first substance use among young people in the US. JAMA Pediatrics, 175(6), 640–643. https://doi.org/10.1001/jamapediatrics.2020.6981